In vivo efficacy of novel monobactam LYS228 in murine models of carbapenemase-producing Klebsiella pneumoniae infection.

In vivo efficacy of novel monobactam LYS228 in murine models of carbapenemase-producing Klebsiella pneumoniae infection.
Antimicrob Agents Chemother. 2019 Jan 14;:
Authors: Weiss WJ, Pulse ME, Nguyen P, Growcott EJ
Abstract
LYS228 has potent antibacterial activity against carbapenem-resistant strains of Enterobacteriaceae. LYS228 was efficacious in neutropenic thigh models established with K. pneumoniae producing either KPC-2 or NDM-1; pre-treatment with uranyl nitrate considerably shifted calculated static doses of LYS228. In murine ascending pyelonephritis, LYS228 reduced bacterial burden in the kidney, urine and bladder. The successful treatment of murine infection models established with carbapenem resistant K. pneumoniae further supports the clinical development of LYS228.
PMID: 30642927 [PubMed - as supplied by publisher]

Source: Antimicrobial Agents and Chemotherapy - January 14, 2019 Category: Microbiology Authors: Weiss WJ, Pulse ME, Nguyen P, Growcott EJ Tags: Antimicrob Agents Chemother Source Type: research